Name (Synonyms) | Correlation | |
---|---|---|
drug1265 | Isotonic saline 0.9% Wiki | 1.00 |
drug1886 | Povidone-Iodine 2% Wiki | 1.00 |
drug1853 | Placebo oral tablet Wiki | 0.19 |
drug1086 | Hydroxychloroquine Wiki | 0.10 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."
Description: Nasopharyngeal swabs will be obtained and quantitative polymerase chain reaction (PCR) testing will be performed to determine the viral load in the nasopharynx
Measure: Mean change in viral titers of SARS-CoV-2 Time: Day 1 (baseline), Day 1 (4 hours), Day 5Description: Adverse effects of interest include: Nasal burning/pain Headaches Ear pain Sneezing Nose bleeds
Measure: Frequency of adverse effects of interest after nasal sprays Time: Up to 5 daysDescription: Symptoms of interest include: Fever Fatigue Change in smell Change in taste Nasal obstruction Chills Sore throat
Measure: Frequency of symptoms related to SARS-CoV-2 Time: Up to 5 daysDescription: Self report by participants (survey) of estimated doses completed.
Measure: Compliance with study drug administration Time: Up to 5 daysDescription: Participants scratch the cards and attempt to identify the smell from a multiple choice set of options. Their scores are then computed and categorized as normal, mild, moderate, or severe microsmia (loss of smell).
Measure: Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT) Time: Day 1 (baseline), Day 30